Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts
Monique Topp(Walter and Eliza Hall Institute of Medical Research), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), David D.L. Bowtell(The University of Melbourne), Lynne Hartley(Walter and Eliza Hall Institute of Medical Research), Karla J. Hutt(Discovery Institute), Kathryn Alsop(Peter MacCallum Cancer Centre), Lauren McShane(Walter and Eliza Hall Institute of Medical Research), Emma Boehm(Walter and Eliza Hall Institute of Medical Research), Michele Cook(Walter and Eliza Hall Institute of Medical Research), Scott H. Kaufmann(Mayo Clinic), Laura Galletta(Peter MacCallum Cancer Centre), Valerie Heong(Walter and Eliza Hall Institute of Medical Research), Marisol Harrell(University of Washington), Elizabeth M. Swisher(University of Washington), Dariush Etemadmoghadam(Peter MacCallum Cancer Centre), Stephen B. Fox(Peter MacCallum Cancer Centre), Orla McNally(Royal Women's Hospital), Sumitra Ananda(Royal Women's Hospital), Gillian Mitchell(Peter MacCallum Cancer Centre), Matthew J. Wakefield(The University of Melbourne), J. B. Kerr(Barrie Urology Group), Jan Pyman(Royal Women's Hospital)
Cited by 141
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k